New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
10:38 EDTENDP, BDSIEndo Health trial results more meaningful to partner, says Cantor
Cantor views the positive top-line results from the trial of BEMA buprenorphine reported by Endo Health (ENDP) as more meaningful to its partner, BioDelivery Sciences (BDSI), than to Endo. Cantor see the product opportunity for this drug to be modest and maintains its Sell rating and $43 price target on Endo Health.
News For ENDP;BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
08:04 EDTBDSIBioDelivery Sciences to develop opioid dependence injection with Evonik
Subscribe for More Information
October 23, 2014
10:01 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:55 EDTENDPEndo initiated with a Buy at Guggenheim
Subscribe for More Information
October 21, 2014
06:37 EDTENDPEndo pullback brings buying opportunity, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use